50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#27

Liraglutide

Weight ManagementVictozaSaxendaNN2211

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management, predating semaglutide as the first GLP-1 agonist approved specifically for obesity.

Share:

Overview

Liraglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk with 97% homology to native human GLP-1. A fatty acid modification extends its half-life to approximately 13 hours for once-daily dosing. It pioneered the GLP-1 agonist class and paved the way for semaglutide.

FDA-approved in 2010 as Victoza for type 2 diabetes and in 2014 as Saxenda for weight management, liraglutide stimulates insulin secretion and suppresses glucagon in a glucose-dependent manner. The SCALE trial program showed mean weight loss of approximately 8% with Saxenda, and the LEADER trial demonstrated cardiovascular benefits.

While surpassed by semaglutide in efficacy and public attention, liraglutide retains clinical importance. Its decade-plus safety record, pediatric obesity approval (Saxenda for ages 12+), and once-daily dosing maintain its relevance. It serves as an important option for patients who cannot tolerate newer agents.

Liraglutide also demonstrated a 79% reduction in progression from prediabetes to type 2 diabetes over 3 years, highlighting metabolic benefits beyond weight loss alone. Generic versions and biosimilars are beginning to reach the market.

Research Uses & Applications

  • FDA-approved treatment for type 2 diabetes (as Victoza)
  • FDA-approved for weight management in adults and adolescents 12+ (as Saxenda)
  • Cardiovascular risk reduction in type 2 diabetes
  • Prediabetes to diabetes progression prevention
  • Pediatric obesity treatment
  • Glycemic control with low hypoglycemia risk

Key Research Findings

  • The SCALE trial showed liraglutide 3.0 mg produced mean weight loss of 8% vs 2.6% placebo over 56 weeks (NEJM, 2015).
  • The LEADER trial demonstrated 13% reduction in major adverse cardiovascular events (NEJM, 2016).
  • Liraglutide reduced progression from prediabetes to type 2 diabetes by 79% over 3 years.
  • Studies in adolescents showed significant BMI reduction supporting pediatric approval.
  • Over a decade of post-marketing safety data has established a well-characterized side effect profile.

Risks & Side Effects

  • Gastrointestinal side effects are common, especially during dose escalation.
  • Boxed warning for thyroid C-cell tumor risk based on rodent studies.
  • Risk of pancreatitis with ongoing monitoring recommended.
  • Gallbladder-related events including gallstones may occur.
  • Requires daily injection, less convenient than weekly alternatives.

Administration

Once-daily subcutaneous injection. For diabetes (Victoza): 0.6 mg daily increasing to 1.2-1.8 mg. For weight management (Saxenda): 0.6 mg daily increasing by 0.6 mg weekly to 3.0 mg target. Injected in abdomen, thigh, or upper arm at any time of day.

Legal Status

FDA-approved prescription medication. Victoza for diabetes and Saxenda for weight management. Available by prescription only. Also approved by EMA and most regulatory agencies. Biosimilars are entering the market.

Frequently Asked Questions

What is Liraglutide?

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management, predating semaglutide as the first GLP-1 agonist approved specifically for obesity.

What are the main uses of Liraglutide?

The primary research applications of Liraglutide include: FDA-approved treatment for type 2 diabetes (as Victoza); FDA-approved for weight management in adults and adolescents 12+ (as Saxenda); Cardiovascular risk reduction in type 2 diabetes; Prediabetes to diabetes progression prevention; Pediatric obesity treatment; Glycemic control with low hypoglycemia risk.

What are the risks and side effects of Liraglutide?

Documented risks and side effects include: Gastrointestinal side effects are common, especially during dose escalation.; Boxed warning for thyroid C-cell tumor risk based on rodent studies.; Risk of pancreatitis with ongoing monitoring recommended.; Gallbladder-related events including gallstones may occur.; Requires daily injection, less convenient than weekly alternatives.. Always consult a healthcare professional before considering any peptide.

Is Liraglutide legal?

FDA-approved prescription medication. Victoza for diabetes and Saxenda for weight management. Available by prescription only. Also approved by EMA and most regulatory agencies. Biosimilars are entering the market.

How is Liraglutide administered?

Once-daily subcutaneous injection. For diabetes (Victoza): 0.6 mg daily increasing to 1.2-1.8 mg. For weight management (Saxenda): 0.6 mg daily increasing by 0.6 mg weekly to 3.0 mg target. Injected in abdomen, thigh, or upper arm at any time of day.

Related Peptides

#2

Semaglutide

Weight Management

#3

Tirzepatide

Weight Management

#10

AOD-9604

Weight Management

#42

Retatrutide

Weight Management

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #26 Follistatin 344#28 Oxytocin →